Results 1 to 10 of about 38,006 (160)

Stimulant use disorder diagnosis and opioid agonist treatment dispensation following release from prison: a cohort study [PDF]

Substance Abuse Treatment, Prevention, and Policy, 2022
Background Concurrent opioid and stimulant use is on the rise in North America. This increasing trend of use has been observed in the general population, and among people released from prison in British Columbia (BC), who face an elevated risk of ...
Heather Palis, Bin Zhao, Pam Young, Mo Korchinski, Leigh Greiner, Tonia Nicholls, Amanda Slaunwhite   +6 more
doaj   +2 more sources

Feasibility of Testing Client Preferences for Accessing Injectable Opioid Agonist Treatment (iOAT): A Pilot Study

Patient Preference and Adherence, 2022
Sophia Dobischok,1 Rebecca K Metcalfe,1 Elizabeth Angela Matzinger,1 Kurt Lock,1,2 Scott Harrison,3 Scott MacDonald,3 Sherif Amara,4 Martin T Schechter,1,5 Nick Bansback,1,5 Eugenia Oviedo-Joekes1,5 1Centre for Health Evaluation & Outcome Sciences ...
Dobischok S, Metcalfe RK, Matzinger EA, Lock K, Harrison S, MacDonald S, Amara S, Schechter MT, Bansback N, Oviedo-Joekes E   +9 more
doaj   +3 more sources

A cohort study evaluating the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention for patients in opioid agonist treatment (OAT) across Ontario, Canada, using administrative health data [PDF]

Harm Reduction Journal, 2020
Background Due to the high prevalence of mental disorders among people with opioid use disorder, the objective of this study was to determine the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention ...
Kristen A. Morin, Joseph K. Eibl, Graham Gauthier, Brian Rush, Christopher Mushquash, Nancy E. Lightfoot, David C. Marsh   +6 more
doaj   +2 more sources

The impact of opioid agonist treatment on fatal and non-fatal drug overdose among people with a history of opioid dependence in NSW, Australia, 2001-2018: findings from the OATS retrospective linkage study.

International Journal of Population Data Science, 2022
Objectives There are critical periods of mortality risk at onset and cessation of opioid agonist treatment. We aim to determine whether non-fatal overdose followed the same pattern as fatal overdose, comparing the first 4 weeks of treatment and ...
Nicola Jones, Louisa Degenhardt, Matthew Hickman, Suzanne Nielsen, Sarah Larney, Timothy Dobbins, Robert Ali   +6 more
doaj   +3 more sources

Persisting high rates of mental health disorders in patients in opioid agonist treatment-Results from a 6-year longitudinal study. [PDF]

Am J Addict
Soyka M, Koller G, Hans-Ulrich W, Bühringer G.   +3 more
europepmc   +2 more sources

Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the “Bernese method”

Substance Abuse and Rehabilitation, 2016
Robert Hämmig,1 Antje Kemter,2 Johannes Strasser,2 Ulrich von Bardeleben,1 Barbara Gugger,1 Marc Walter,2 Kenneth M Dürsteler,2 Marc Vogel2 1Division of Addiction, University Psychiatric Services Bern, Bern, Switzerland; 2Division of Substance ...
Hämmig R, Kemter A, Strasser J, von Bardeleben U, Gugger B, Walter M, Dürsteler KM, Vogel M   +7 more
doaj   +1 more source

Disparities in Opioid Agonist Treatment Accessibility for Priority Populations in New South Wales, Australia. [PDF]

Drug Alcohol Rev
Conigrave JH, Dobbins T, Buckley NA, Lee KSK, Morley KC, Doyle M, Al-Ansari B, Wilson S, Loggins S, Conigrave K.   +9 more
europepmc   +3 more sources

Comparative effectiveness of take-home dosing schedules for opioid agonist treatment in British Columbia, Canada: a target trial emulation protocol using a population-based observational study. [PDF]

BMJ Open
Kurz M, Guerra-Alejos BC, Hossain MB, Min JE, Yan R, Bruneau J, Catherine NLA, Greenland S, Gustafson P, Hedden L, Karim E, McCandless L, Nolan S, Platt RW, Bach P, Seaman S, Siebert U, Socías ME, Nosyk B.   +18 more
europepmc   +3 more sources

What is the benefit of inconsistent opioid agonist treatment in patients with prescription opioid use disorder?

European Psychiatry, 2023
Introduction Studies consistently show that patients with prescription opioid use disorder (OUD) respond to buprenorphine treatment. Few studies have followed these patients in the long-term.
R. Weiss, M. L. Griffin
doaj   +1 more source

Primary care physician characteristics associated with becoming opioid agonist treatment prescribers in British Columbia: a retrospective case-control study. [PDF]

Harm Reduct J
Panagiotoglou D, Peterson S, Lavergne MR, Gomes T, Chadha R, Johnson C, McCracken R.   +6 more
europepmc   +3 more sources